ERBB2 and non-small cell lung carcinoma: For instance, T-DXd combined with durvalumab (an anti-PD-L1 ICI) is currently being evaluated in HER2-positive breast cancer and NSCLC, with preliminary findings suggesting potential clinical activity (DESTINY-Breast07, NCT04538742; DESTINY-Lung03, NCT04686305).